College of Pharmacy, The University of Texas at Austin, Austin, TX, United States of America.
Pharmacotherapy Education and Research Center, The University of Texas Health San Antonio, San Antonio, TX, United States of America.
PLoS One. 2018 Nov 30;13(11):e0208461. doi: 10.1371/journal.pone.0208461. eCollection 2018.
Gastric acid suppressants are commonly used in the United States, and while generally well-tolerated, long-term use has been associated with infection, bone fractures, and nutrient malabsorption. The purpose of this study was to describe national trends in gastric acid suppressant use over a 7-year period.
This was a cross-sectional study using data from the National Ambulatory Medical Care Survey from 2009 to 2015. Gastric acid suppressant use was defined as any outpatient visit with a documented prescription for a proton pump inhibitor or histamine-2 receptor antagonist documented during the outpatient visit. Sample data weights were used to extrapolate to national estimates. Use was calculated as the number of prescriptions per total outpatient visits per year. Appropriateness of prescribing was assessed using FDA-approved indications listed in each visit.
These data represent 6.8 billion patient outpatient visits between 2009 and 2015, of which nearly 600 million (8.8%) had documented gastric acid suppressant use. The median (IQR) age of gastric acid suppressant users and non-gastric acid suppressant users was 62 (50-73) and 49 (25-65), respectively. Gastric acid suppressant use decreased from 9.0% in 2009 to 7.7% in 2012, and then increased to 9.7% in 2015. Proton pump inhibitor use was slightly higher in the Midwest (8.3%). Only 15.8% of gastric acid suppressant users had a documented indication.
Proton pump inhibitor use increased after 2012, and the majority of gastric acid suppressant users did not have a documented indication. Judicious gastric acid suppressant prescribing needs to be exercised, especially in the context of new safety data regarding long-term proton pump inhibitor use.
在美国,胃酸抑制剂被广泛使用,虽然通常耐受性良好,但长期使用与感染、骨折和营养吸收不良有关。本研究的目的是描述胃酸抑制剂使用在 7 年内的全国趋势。
这是一项使用 2009 年至 2015 年全国门诊医疗调查数据的横断面研究。胃酸抑制剂的使用定义为任何门诊就诊时记录有质子泵抑制剂或组胺 2 受体拮抗剂处方的就诊。使用样本数据权重进行外推以获得全国估计值。使用情况按每年每 10000 次门诊就诊中开具的处方数计算。通过每个就诊中列出的 FDA 批准的适应症评估处方的适宜性。
这些数据代表 2009 年至 2015 年间 68 亿患者的门诊就诊,其中近 6 亿(8.8%)记录有胃酸抑制剂的使用。胃酸抑制剂使用者和非胃酸抑制剂使用者的中位数(IQR)年龄分别为 62(50-73)和 49(25-65)。胃酸抑制剂的使用从 2009 年的 9.0%下降到 2012 年的 7.7%,然后在 2015 年增加到 9.7%。中西部地区质子泵抑制剂的使用略高(8.3%)。只有 15.8%的胃酸抑制剂使用者有记录的适应症。
质子泵抑制剂的使用在 2012 年后增加,大多数胃酸抑制剂使用者没有记录的适应症。需要谨慎开具胃酸抑制剂处方,特别是在长期使用质子泵抑制剂的新安全性数据的背景下。